[
    {
        "age": null,
        "album": "",
        "author": null,
        "bookmarked": false,
        "comments": [],
        "date_dead_since": null,
        "date_published": "2025-01-25T15:27:49+00:00",
        "description": "Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the PhaseIII BREAKWATER trial.",
        "id": 1979785,
        "language": "en-us",
        "link": "https://www.sciencedaily.com/releases/2025/01/250125152749.htm",
        "manual_status_code": 0,
        "page_rating": 27,
        "page_rating_contents": 86,
        "page_rating_visits": 0,
        "page_rating_votes": 0,
        "permanent": false,
        "source__id": 188,
        "source_url": "https://www.sciencedaily.com/rss/all.xml",
        "status_code": 0,
        "tags": [],
        "thumbnail": null,
        "title": "Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer",
        "vote": 0
    }
]